Replies to post #179167 on Biotech Values

[linhdtu]

LOL. 3.2M$ insider sells immediately 1 day after the Idix BO announcement is certainly no confidence builder for the poor retailers wanting to pile in.

I would watch Achn form4 filings like a hawk for a while if I want to pile into it.

[frontiers]

ACHN. You can read the tea leaves on that 370K sale by one insider if you want.

I am content to rely on the preclinical data on 3422, how it compares vs sofosbuvir, and its lack of toxicity.

[DewDiligence]

ACHN—RA Capital sold $7.4M worth of stock on 6/20/14 at $8.30-8.41:

http://www.sec.gov/Archives/edgar/data/1070336/000114420414039302/xslF345X03/v382240_4.xml

RA Capital still owns 22.5M shares of ACHN (~$170M worth), an equity stake of 23% (http://www.sec.gov/Archives/edgar/data/1070336/000114420414039304/v382212_sc13da.htm ).

[frontiers]

Looked like some insiders don't want to bet on that success at all:

Completely and totally WRONG conclusion, IMO!!

OK, they sold 800,000 shares in the 8s for some profit taking to appease their own investors -- that's only 3.4% of their total holdings in ACHN. They still own 222.49 million shares.

BTW, Pete Kolchinsky (RA) and Dan Gold (QVT) own ~35% of ACHN between them ... they have sold a small % for profit taking during the recent run up, they are holding the vast majority ... for very good reasons!!!

Note that the above total % holdings is about same as Baupost holdings in Idenix.

Yes, ACHN is a prime buyout candidate ... for its nuke (3422)!!!

[DewDiligence]

RA Capital sold ~$14M of ACHN this week in addition to ~$27M last week:

http://www.sec.gov/Archives/edgar/data/1070336/000114420414059052/xslF345X03/v390523_form4.xml
http://www.sec.gov/Archives/edgar/data/1070336/000114420414058131/xslF345X03/v390171_4.xml

[DewDiligence]

ACHN raised $50M in December via ATM with Cantor Fitzgerald (8-K filing today, but no PR):

http://www.sec.gov/Archives/edgar/data/1070336/000119312515007325/d850311d8k.htm

Between December 22, 2014 and December 31, 2014, Achillion Pharmaceuticals, Inc. sold shares of its common stock pursuant to the Sales Agreement, dated November 8, 2012, between the Company and Cantor Fitzgerald & Co., resulting in aggregate gross proceeds to the Company of $50 million. After giving effect to these sales, the Company estimates that its cash will be sufficient to meet its projected operating requirements into the fourth quarter of 2016.

ACHN clearly tried to hide this news amid the cornucopia of news flow from JPM. Sleazy.